Factors that affect prognosis The AJCC has identified several factors that affect prognosis of bone<unk> s: * Size of the tumor: larger tumors tend to have a worse prognosis compared to smaller tumors. * Spread of tumor to surrounding tissues: tumors that have spread locally to surrounding tissues tend to have a worse prognosis compared to tumors that have not spread beyond their place of origin. * Stage and presence of metastases: tumors that have spread ("metastasized") to the lymph nodes (which is rare for bone<unk> s) or other organs or tissues (for example, to the lungs) have a worse prognosis compared to tumors that have not metastasized. * Tumor grade: higher grade tumors (grades 2 and 3) tend to have a worse prognosis compared to low grade (grade 1) tumors. * Skeletal location: tumors originating in the spine or pelvic bones tend to have a worse prognosis compared to tumors originating in arm or leg bones. For soft tissue<unk> s other than GISTs, factors that affect prognosis include: * Stage: as with bone<unk> s, tumors that have metastasized have a worse prognosis compared to tumors that have not metastasized. * Grade: the AJCC recommends using a grading system called the French Federation of Cancer Centers<unk>  Group (FNCLCC) Grade for soft tissue<unk> s, with high-grade tumors having a worse prognosis compared to low-grade tumors. For GISTs, the key factor that affects prognosis is: * Mitotic rate: mitotic rate refers to the fraction of cells that are actively dividing within the tumor; GISTs that have a high mitotic rate have a worse prognosis compared to GISTs that have a low mitotic rate. Outcome data According to data published by the US National Cancer Institute (NCI), the overall 5-year survival for bone<unk> s is 66.9%. The American Cancer Society (ACS) estimates that 1,660 people in the US will die in 2019 from bone<unk> s, accounting for 0.3% of all cancer deaths. The median age at death is 61 years old, although death can occur in any age group. Thus, 12.3% of bone<unk>  deaths occur in people under 20 years old, 13.8% occur in people 20–34 years old, 5.5% occur in people 35–44 years old, 9.3% occur in people 45–54 years old, 13.5% occur in people 55–64 years old, 16.2% occur in people 65–74 years old, 16.4% occur in people 75–84 years old, and 13.1% occur in people 85 years or older. For soft tissue<unk> s, the overall 5-year survival (irrespective of stage) is 64.5%, but survival is affected by many factors, including stage. Thus, the 5-year survival is 80.8% for soft tissue<unk> s that have not spread beyond the primary tumor ("localized" tumors), 58.0% for soft tissue<unk> s that have spread only to nearby lymph nodes, and 16.4% for soft tissue<unk> s that have spread to distant organs. The ACS estimates that 5,270 people will die from soft tissue<unk>  in 2019, accounting for 0.9% of all cancer deaths.
Sarcoma
Angiosarcoma
Soft-tissue sarcoma
Hemangiosarcoma
Xanthoma
Myosarcoma
Epithelioma
Liposarcoma